Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02039076 · ClinicalTrials.gov registry record · Phase 1
A Five-Treatment-Period Study to Evaluate the Single-Dose Pharmacokinetics and Pharmacodynamics of Avatrombopag in Healthy Japanese and White Subjects
A Phase 1 study of Thrombocytopenia, sponsored by Eisai.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
- 1
- Study location
NCT02039076 is a Phase 1 study of Thrombocytopenia that has completed, run by Eisai. The registered enrollment target is 48 participants, below the 310-participant average among 20 other Thrombocytopenia trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02039076, a Phase 1 study of Thrombocytopenia, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
- 1
- Study location
Study Summary
This will be a randomized, open-label, 5-treatment-period study to evaluate the PK and PD of avatrombopag following a single administration of avatrombopag in the fed and fasted condition, or the fed condition, to healthy Japanese and white subjects. A standard high-fat, high calorie breakfast will be used to assess the fed condition.
Conditions Studied
Interventions
- DRUG avatrombopag
Study Locations (1)
California
- Parexel International Early Development Clinical Units - Glendale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2013-12 |
| Est. Completion | 2014-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02039076
The ClinicalTrials.gov registry entry for NCT02039076 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 310-participant average among 20 other Thrombocytopenia trials with a reported enrollment target (85% lower). The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Thrombocytopenia appearing as the primary indexed condition, and to 1 intervention - of which avatrombopag is the first listed.
NCT02039076 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT02039076 about?
NCT02039076 is a clinical study titled "A Five-Treatment-Period Study to Evaluate the Single-Dose Pharmacokinetics and Pharmacodynamics of Avatrombopag in Healthy Japanese and White Subjects". This will be a randomized, open-label, 5-treatment-period study to evaluate the PK and PD of avatrombopag following a single administration of avatrombopag in the fed and fasted condition, or the fed condition, to healthy Japanese and white subjects. A standard high-fat, high calorie breakfast will ...
What is the current status of trial NCT02039076?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2013-12. Estimated completion is 2014-09.
What conditions does trial NCT02039076 study?
This clinical trial studies the following conditions: Thrombocytopenia.
What interventions are being tested in trial NCT02039076?
The interventions under investigation include: avatrombopag (DRUG).
Who is sponsoring clinical trial NCT02039076?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02039076 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thrombocytopenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation or Isotretinoin in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Acute Lymphocytic Leukemia
COMPLETED · Phase 1
-
Busulfan, Antithymocyte Globulin, and Fludarabine Followed By a Donor Stem Cell Transplant in Treating Young Patients With Blood Disorders, Bone Marrow Disorders, Chronic Myelogenous Leukemia in First Chronic Phase, or Acute Myeloid Leukemia in First Remission
COMPLETED · Phase 1
-
177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia
RECRUITING · Phase 2
-
Luspatercept for Clonal Cytopenias of Uncertain Significance
RECRUITING · Phase 2
-
Platelet-Directed Whole Blood Transfusion Strategy for Malaria
RECRUITING · NA
-
Apixaban in Thrombocytopenia
RECRUITING · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.